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ABSTRACT   27 
Thymus capitatus represents one of the five Tunisian species of the genus Thymus, 28 
which has long standing use for flavouring and preserving several food products. Its 29 
constituents have been reported to endow antimicrobial properties, but little is known 30 
about their antiviral activities. The aim of this study was to examine the antiviral 31 
activity of pure compounds from the most bioactive inhibitory Thymus capitatus extract 32 
in vitro against HSV-2 infection and to identify their mechanism of action. Either the 33 
extracts or the essential oil exert inhibitory activity against HSV-2 infection, with the 34 
ethanolic extract showing the lowest EC50 value (2.3g/ml). Three pure compounds 35 
were then isolated from the ethanolic extract and investigated for their antiviral activity.  36 
β-sitosterol showed the most favorable selectivity index and both cinnamaldehyde and 37 
carvacrol exerted moderate antiviral effect. Investigation of the mechanism of action 38 
revealed that all three compounds directly inactivated the infectivity of the virus 39 
particles. These findings suggest the use of  Thymus capitatus ethanolic extract as 40 
source of anti-HSV-2 pure compounds and warrant further studies to evaluate their 41 
therapeutic potential. 42 
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Introduction 75 
The Thymus genus is considered to be one of the largest genera within the Lamiaceae 76 
family that includes approximately 350 species of perennial, aromatic herb and sub 77 
shrubs native mainly of Europe, Western Asia and the Mediterranean regions (Stahl-78 
Biskup & Saez, 2002). Thymus capitatus (Hoffmanns. & Link, Lamiaceae) represents 79 
one of the five Tunisian species of the genus Thymus, which has a long standing use for 80 
flavouring and preserving several food products. Its essential oil is used in the 81 
flavouring cough medicines and oral hygiene products as well as in cosmetic and 82 
perfume industry. As a medicinal plant, T. capitatus decoction and infusion have 83 
traditionally been considered as antispasmodic, carminative, tonic, antiseptic and 84 
antitussive drugs (Chiej, 1984). Numerous reports showed antibacterial, antifungal, 85 
antioxidant and anti-inflammatory properties of T. capitatus extracts and essential oil, 86 
rich in carvacrol and thymol (Mkaddem et al., 2010; Achour et al., 2012; Iauk et al., 87 
2014; Maissa et al., 2015). To date, extracts of several species of Thymus, as T. vulgaris 88 
and T. linearis, have been investigated for their anti-herpetic effect, even though the 89 
constituents responsible of the antiviral activity have not been yet identified (Nolkemper 90 
et al., 2006; Schnitzler et al., 2007; Koch et al., 2008; Rajbhandari et al., 2009). Herpes 91 
simplex virus type 2 (HSV-2) is a sexually transmitted pathogen that infects about 417 92 
million people aged 15-49 (11%) worldwide, causing genital infections (www.who.int). 93 
Most of these infections are asymptomatic but can also cause painful blisters or ulcers at 94 
the site of infection. Symptomatic infections are most contagious but sexually 95 
transmission can also occur in the absence of symptoms (Roizman, Knipe & Whitley 96 
2007). Of note, genital ulcer disease increases the risk of HIV acquisition since the 97 
mucosal damage induces local inflammation, following activation and recruitment of 98 
5 
 
CD4+ HIV target cells (Freeman et al., 2006; Corey, 2007; Feng et al., 2013). Although 99 
different anti-herpetic drugs are approved and used to treat acute symptomatic 100 
infections (acyclovir, penciclovir and other guanine analogues), the development of new 101 
antivirals against HSV-2 is needed due to several drawbacks of available drugs. These 102 
include the emergence of drug resistant strains, the inability to eradicate latent 103 
infections, the poor availability and the incomplete intestinal absorption (Kimberlin & 104 
Whitley, 2007; Cavalli et al., 2012). In this context, alternative natural products from 105 
plants have been explored, as sources of antiviral molecules endowed with a mechanism 106 
of action different from that of acyclovir (Silva-Mares et al., 2016). 107 
Herein, we investigated the antiviral activity of aqueous extract, ethanolic extract and 108 
essential oil of T. capitatus against HSV-2. -sitosterol, cinnamaldehyde and carvacrol 109 
derived from the ethanolic extract, have been identified as inhibitory compounds against 110 
acyclovir sensitive and resistant HSV-2 strains and their mechanism of action has been 111 
analyzed. 112 
 113 
Materials and methods 114 
Plant identification and collection 115 
Fresh T. capitatus (Hoffmanns. & Link, Lamiaceae) plants were collected in May 2014 116 
from Matmata locality in the South East of Tunisia (33° 32′ North 9°58′ East). Plants 117 
was identified by Dr. Marwa Mekni Toujiani. Aerial parts of the plants (leaves, stems 118 
and flowers) were separated, thoroughly rinsed in running tap water and air dried at 119 
room temperature during 14 days. A voucher specimen (TC-001) has been deposited in 120 
the herbarium of the Department of Pharmacy of the University “G. d’Annunzio” of 121 
Chieti-Pescara. 122 
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Chemicals 123 
Eagle’s minimal essential medium (MEM) and fetal calf serum (FCS) were purchased 124 
from Gibco/BRL (Gaithersburg, MD, USA) and the antibiotic-antimycotic solution 125 
(Zell Shield) from Minerva Biolabs GmbH (Berlin, Germany). Acyclovir and heparin 126 
were purchased from Sigma-Aldrich (Milan, Italy). 127 
Cells and culture conditions 128 
African green monkey fibroblastoid kidney cells (Vero, ATCC CCL-81) were grown as 129 
monolayers in MEM supplemented with 10% heat inactivated FCS and 1% Zell Shield.  130 
Virus 131 
A clinical isolate of HSV-1 and HSV-2 were kindly provided by Prof. M. Pistello, 132 
University of Pisa, Italy. HSV strains were propagated and, when the cytopathic effect 133 
involves the whole monolayer, the infected cell suspension is collected and the viral 134 
supernatant clarified. The virus stocks were aliquoted, titrated by plaque assay on Vero 135 
cells and stored at -80 °C. A HSV-2 strain with phenotypic resistance to acyclovir was 136 
generated by serial passage in presence of increasing concentrations of acyclovir, as 137 
previously described (Donalisio et al., 2016). 138 
Extracts preparation 139 
The ethanolic and aqueous extracts (EE and AE) were prepared as previously described 140 
(Boubaker–Elandalousi et al., 2014). The essential oil (EO) was prepared by dissolving 141 
100 g of dried plant material in 1 liter of distilled water and then submitted to 142 
microwave-assisted hydro-distillation at 40 °C during 4 h, in a Clevenger type 143 
apparatus. Extracts were kept in a dark flask at 4 °C until tested. Working solutions (25 144 
mg ml−1) of EO and EE were dissolved in dimethyl sulfoxide (DMSO). Aqueous 145 
extracts were prepared in a similar way by 24 h maceration.  146 
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Isolation of pure compounds from ethanolic extract of  T. capitatus 147 
Isolation and identification of β-sitosterol. The EE (10 g) of the plant was suspended in 148 
n-hexane (50 ml) and the resulting mixture was centrifuged at 5000 g for 3 h then 149 
filtered. The filtrate was evaporated to dryness under vacuum and the resulting waxy 150 
solid dissolved in a 1:1 mixture water: ethanol (50 ml) and extracted with n-hexane 151 
(5x10 ml) and this latter evaporated to dryness under vacuum. The obtained powder was 152 
subjected to purification on a silica gel column chromatography using hexane: 153 
dichloromethane 9:1 as the eluent. β-sitosterol (25 mg, purity > 96.3% assayed by 154 
HPLC (Figure 1A) following an already reported method (Kakade et al., 2012) was 155 
obtained as a white solid and its structure was confirmed by TLC and NMR 156 
spectroscopy by comparison with an authentic sample.  157 
Isolation and identification of cinnamaldehyde and carvacrol. The EE (0.5 g) of the 158 
plant was subjected to silica gel column chromatography using dichloromethane and 159 
95% dichloromethane / 5% methanol mixture as the eluents. Cinnamaldehyde (10mg, 160 
purity > 97.4% assayed by HPLC (Figure 1B)) was eluted first and obtained as 161 
yellowish oil and its structure was confirmed by TLC and NMR spectroscopy by 162 
comparison with an authentic sample. Carvacrol (12 mg, purity > 96.7% assayed by 163 
HPLC (Figure 1C)) was eluted as the second spot and got as a yellowish oil and its 164 
structure was confirmed by TLC and NMR spectroscopy by comparison with an 165 
authentic sample. 166 
GC and HPLC analysis 167 
GC analysis of the essential oil have been accomplished following the same general 168 
procedure as recently reported (Ricci et al., 2017). HPLC analysis were carried out 169 
using a Waters 600 HPLC system equipped with a Waters 2996 PDA detector, a 170 
8 
 
Rheodyne manual syringe-loading valve injector model 7125 (Cotati, CA., USA) fitted 171 
with a 20 μL loop. Data acquisition was monitored by Waters Empower software (ver. 172 
2.0). Chromatographic separation was accomplished employing a GraceSmart RP18 (5 173 
m particle size, 250 mm x 4.6 mm, Grace, Deerfield, IL, USA). Column temperature 174 
was maintained at 25 ± 1 °C using a cool pocket chiller (ThermoScientific, Waltham, 175 
USA). Elution mixture consisted of H2O and acetonitrile both with 0.1% of formic acid 176 
(eluent A and eluent B, respectively). Mobile phase was directly on-line degassed by an 177 
Infinity Agilent model 1260 (Agilent Technologies, Santa Clara, CA, USA). The flow 178 
rate was 1.20 mL/min. The following gradient elution was used: 15% A – 85% B from 179 
0.01 min. to 13.0 min., 40% A – 60% from 13.01 min. to 16.0 min., 60% A – 40% B 180 
from 16.01 min. to 20.0 min., 80% A – 20% B from 20.01 min. to 23.0 min., 90% A – 181 
10% B from 23.01 min. to 26.0 min. The injection volume was 20 L. Samples were 182 
filtered through a 0.45 μm membrane polyamide filter before injection. 183 
Method validation was settled according to the “Guidance for Industry-Bioanalytical 184 
Method Validation” recommended by Food and Drug Administration (FDA) of the 185 
United States. Individual stock solutions for calibration curves of each chemical 186 
standard were prepared by dissolution of 10 mg of each reference sample into 10mL of 187 
MeOH. The resulting solution was stored in glass-stoppered bottles at 4 °C before each 188 
HPLC run. Standards for calibration curves and quality control samples (QC), at 189 
concentration of 1.0, 10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0 and 100.0 190 
μg/mL, were daily prepared by appropriate dilution aliquots of the stock solutions in 191 
MeOH. Pooled quality control samples of analytes were prepared to determine the limit 192 
of quantification (LOQ), the intra-and inter-assay precision and accuracy of the method, 193 
and to assess the stability of compounds when stored under different conditions. QC 194 
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samples at three different concentration levels (QClow= 5.0, QCmedium = 45.0, and 195 
QChigh=95.0 μg/mL) were used to validate or reject the analytical run. On five separate 196 
days, six calibration curves were plotted against the corresponding concentrations. 197 
Correlation coefficients, slopes, and intercepts of each calibaration curve were also 198 
evaluated. The limit of detection (LOD), defined as 3 times the standard deviation of a 199 
blank samples divided by the analytical sensitivity, was calculated from the calibration 200 
graphic following the the guidelines provided by IUPAC s. The LOQ was defined as the 201 
lowest concentration on the calibration curve, which could measured (n=5) with a 202 
precision (RSD %) not exceeding 20% and with an accuracy between 80% and 120% 203 
(Fiorito et al., 2017; Taddeo et al., 2017). 204 
Viability assay 205 
Cell viability was measured using the MTS assay as described by Pauwels et al. (1988). 206 
The effect on cell viability of the different concentrations was expressed as a 207 
percentage, by comparing absorbance of treated cells with that of cells incubated with 208 
culture medium supplemented with equal volume of DMSO. The 50% cytotoxic 209 
concentrations (CC50) and the 95% confidence intervals (CIs) were determined using 210 
Prism software (Graph-Pad Software, San Diego, CA).  211 
Anti-HSV inhibition assay 212 
The effect of T. capitatus extracts, isolated compounds or acyclovir on HSV infection 213 
was evaluated by plaque reduction assay (Novoa et al., 2016). Vero cells were seeded in 214 
24-well plates at a density of 10x104 cells/well. Increasing concentrations of extracts or 215 
constituents were added to cells for 2 h; a mixture of different tested substances plus 216 
HSV-1 or HSV-2 or acyclovir resistant HSV-2  at a multiplicity of infection (MOI) of 217 
0.001 plaque-forming units (PFU)/cell (100 PFU), were subsequently added to the cells, 218 
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which were then incubated at 37 °C for 2 h. The virus inoculum was then removed and 219 
the cells washed and overlaid with a medium containing 1.2% methylcellulose (Sigma-220 
Aldrich) and serial dilutions of extracts or constituents. For acyclovir antiviral assay, the 221 
compound was added only after infection, diluted in the medium containing 222 
methylcellulose as described before. After 24 h (HSV-2) or 48 h (HSV-1) of incubation 223 
at 37°C, cells were fixed and stained by using 20% ethanol and 0.1% crystal violet and 224 
viral plaques counted. A longer incubation time was used for HSV-1 since this clinical 225 
strain generated viral plaques with smaller size than those of HSV-2 at 24 hpi, not 226 
suitable for the count. The concentration that reduced the plaque formation by 50% 227 
(EC50) was determined by comparing treated and untreated wells using Prism software. 228 
Three independent experiments were performed in duplicate.  229 
Virus yield reduction assay 230 
 Vero cells seeded in 24-well plates at a density of 10x104 cells/well were pre-treated 231 
with serial dilutions of pure compounds for 2 h at 37 °C and infected in duplicate with 232 
HSV-2 at a MOI of 0.01 PFU/cell in the presence of the compounds. Following 233 
adsorption at 37 °C for 2 h, the virus inocula was removed and cultures were grown in 234 
the presence of compounds until control cultures displayed extensive cytopathology. 235 
Supernatants were harvested and pooled 48 h after infection and cell-free virus 236 
infectivity titers were determined. The aim of the assay was to obtain, if possible, the 237 
effective concentration of compound that reduced virus yield by 50% (EC50) as 238 
compared to untreated virus controls. 239 
Virus inactivation assay 240 
Approximately, 105 PFU of HSV-2 plus EC90 of pure compounds were added to MEM 241 
and mixed in a total volume of 110 μl. The virus-compound mixtures were incubated 242 
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for 0 h or 2 h at 37 °C then diluted serially to the non-inhibitory concentration of 243 
compounds; the residual viral infectivity was determined by titrating virus by plaque 244 
assay on Vero cells, pre-seeded in 96-well plates at a density of 16x104 cells/well 245 
(Alvarez et al., 2009; Alvarez et al., 2015b). 246 
Pre-treatment assay 247 
 Cells were exposed to serial dilutions of pure compounds in a 24-well plate at 37 °C for 248 
two hours. After washing, cells were infected with HSV-2 at 0.001 MOI for 2 h, washed 249 
and treated as for plaque reduction assay (Donalisio et al., 2016). 250 
Attachment assay 251 
Pre-chilled Vero cells were treated with -sitosterol or heparin for 30 min at 4 °C and 252 
then infected with HSV-2 at 0.004 MOI for 2 h at 4 °C in presence of the pure 253 
compound. After three washes with cold MEM to remove unbound virus, cells were 254 
overlaid with 1.2% methylcellulose and shifted to 37 °C. After 24 h incubation, cells 255 
were stained and viral plaques counted (Alvarez et al., 2009; Alvarez et al., 2015b). 256 
Entry assay 257 
The HSV-2 at 0.004 MOI was adsorbed for 2 h at 4 °C on pre-chilled confluent Vero 258 
cells. Cell layers were then washed three times with cold MEM to remove unbound 259 
virus, treated with different concentrations of-sitosterol, and incubated for 3 h at 37 260 
°C. The outer virions were inactivated with acidic glycine for 2 min at room 261 
temperature and the cells were washed three times with warm medium and treated as for 262 
plaque reduction assay (Alvarez et al., 2009; Alvarez et al., 2015b). 263 
Post-treatment assay 264 
Vero cells monolayers in 24-well plate were infected with HSV-2 at 0.001 MOI for 2 h 265 
at 37 °C, followed by two gentle washes to remove unbound virus. Increasing 266 
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concentrations of pure compounds were then added to cultures in 1.2% methylcellulose 267 
medium. Cells were treated as for plaque reduction assay (Donalisio et al., 2013). 268 
Data analysis 269 
All results are presented as the mean values from three independent experiments 270 
performed in duplicate. The EC50 and CC50 values were calculated by regression 271 
analysis using the software GraphPad Prism version 4.0 (GraphPad Software, San 272 
Diego, California, U.S.A.), by fitting a variable slope-sigmoid dose–response curve. 273 
The selectivity index (SI) was calculated by dividing the CC50 by the EC50 value. For 274 
virus inactivation and virus yield reduction assays, the viral infectivity in presence and 275 
absence of pure compounds was compared using a one-way analysis of variance 276 
(ANOVA) followed by Bonferroni test, if P values showed significant differences in 277 
virus titers. Significance was set at the 95% level. 278 
 279 
Results and Discussion 280 
Inhibitory activity of T. capitatus extracts against HSV-1 and HSV-2 infections 281 
Within a project aiming at evaluating the antiviral potential of Tunisian endemic plants, 282 
we investigated the antiviral activity of Thymus capitatus aqueous (AE) and ethanolic 283 
extracts (EE) and essential oil (EO) against HSV-2 infection. To generate dose response 284 
curves, assays were performed by treating cells in presence of decreasing concentrations 285 
of extracts (ranging from 100 μg/ml to 0.13 μg/ml) before, during, and after viral 286 
infection. 24 h post infection, the EC50 was determined by comparing the number of 287 
viral plaques in treated and untreated wells, as described in Materials and Methods. As 288 
reported in Table 1, the AE, EE and EO exerted an antiviral activity, although to a 289 
different extent, with EC50 values of 23.6 μg/ml, 2.3 μg/ml and 18.6 μg/ml, respectively. 290 
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In all cases, the antiviral effect was not a consequence of cytotoxicity since the CC50 291 
values on Vero cells were much higher than the EC50 values. Of note, an inhibitory 292 
effect of these extracts from T. capitatus was also observed against HSV-1, another 293 
member of Alphaherpesvirinae subfamily, showing EC50 values of 23.4 μg/ml, 16.6 294 
μg/ml and 17.6 μg/ml, respectively. Our data evidenced a minor antiviral activity of EE 295 
against HSV-1 rather than that against HSV-2. Although HSV-1 and HSV-2 are 296 
structurally and genetically similar, their sensitivity to antiviral compounds may vary 297 
depending on the strains and cell type used in antiviral assays as reported for instance in 298 
Leary et al. (2002). Similar antiviral results were previously observed against Bovine 299 
Herpesvirus type-1 infection with EC50 values of 164 μg/ml, 47.8 μg/ml and 3.3 μg/ml, 300 
respectively (Boubaker-Elandalousi et al., 2014). These data indicate a broad spectrum 301 
of action of T. capitatus extracts against Herpes viruses. As reported in Table 1, the EE 302 
of T. capitatus showed the most favorable selectivity index (SI) value (26.8) against 303 
HSV-2 infection and, therefore, it was selected as a source of bioactive compounds. 304 
Chemical characterization of extracts and essential oil 305 
All the obtained phytopreparations (EO, EE, and AE) were screened in order to obtain 306 
the respective chemical fingerprint. The essential oil of T. capitatus have been analyzed 307 
by GC-MS using a well established procedure by our group and employed several times 308 
in recent years for the analysis of essential oil (Ricci et al., 2017) (Figure 2).  309 
Inhibitory activity of isolated compounds from T. capitatus ethanolic extract and 310 
their mechanism of action 311 
Data reported in Table 1 indicate that the EE was the most active one against both 312 
viruses under investigation. So we decided to define its phytochemical composition by 313 
isolation and structural characterization of its main components. Three compounds were 314 
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isolated from T. capitatus EE, β-sitosterol, cinnamaldehyde, and carvacrol, and they 315 
were tested for their ability to inhibit the replication of the main cause of genital herpes, 316 
HSV-2. All of them were active against HSV-2 infection in a dose-response manner, 317 
with EC50 values of 2.7 M, 39.7 M and 51.9 M, respectively (Table 2); acyclovir 318 
was tested in parallel as a reference drug. Among these compounds, β-sitosterol showed 319 
the strongest inhibitory activity with a SI value of 76.2. This is an interesting result 320 
since, in a previous study, the same compound isolated from Euphorbia segetalis 321 
exerted very low HSV-2 plaque reduction (Madureira et al., 2003). Our finding is in 322 
agreement with previous data that also showed a strong anti HSV-2 activity for β-323 
sitosterol (Alvarez et al., 2015a). A novel finding is the anti-HSV-2 activity of 324 
cinnamaldehyde (SI: 28.3) reported here for the first time. Finally, the anti-HSV-2 325 
activity of carvacrol (SI: 12.1) confirmed previous findings by Pilau et al. (2011) and 326 
Lai et al. (2012). As shown in Figure 2, carvacrol and cinnamaldehyde, were also found 327 
as components of the EO, however this was not the most active phytopreparation. Such 328 
a discrepancy can be explained by a decrease in bioavailability of both phytochemicals 329 
when part of a complex mixture like an essential oil, that in a certain way can modify 330 
key parameters relevant to the biological activity like solubility in the medium 331 
employed for the antiviral assays. Such an effect has been already described for other 332 
biologically active secondary metabolites (Bakkali et al., 2008). 333 
To evaluate whether the antiviral activity of isolated compounds was correlated to virus 334 
sensitivity to acyclovir, similar experiments were performed using an acyclovir-resistant 335 
HSV-2 (EC50 value of 336.9 M for acyclovir). As reported in Table 2, the resistant 336 
strain was susceptible to β-sitosterol, cinnamaldehyde and carvacrol, with EC50 values 337 
equal to 2.3 M, 73.5 M and 82.2 M, respectively. These data suggest a different 338 
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mode of action of the pure compounds from that of acyclovir, a known inhibitor of the 339 
HSV-2 DNA polymerase, making these molecules a potential starting point for research 340 
and development of new antiviral therapies against HSV-2 infection. Therefore, further 341 
experiments were performed to investigate their major mechanism of action. 342 
Firstly, we investigated the ability of pure compounds to directly inactivate HSV-2 viral 343 
particles. The assay was performed by mixing a virus aliquot containing 105 PFU with a 344 
concentration of each compound that reduced almost completely the virus growth 345 
(>EC90) in the plaque reduction assay. The reduction of the viral titers of treated versus 346 
untreated samples was analyzed at high dilutions at which extracts were no more active. 347 
As reported in Figure 3, experiments were performed by incubating the mixtures for 0 h 348 
or 2 h at 37 °C. Both β-sitosterol and cinnamaldehyde did not show any significant 349 
inhibition when the mixtures were promptly added on the cells without incubation 350 
(Figure 3A and 3B). By contrast, after 2 h incubation, both compounds reduced 351 
significantly the HSV-2 titer by 99% and 91%, respectively. The ability of β-sitosterol 352 
and cinnamaldehyde to directly inactivate HSV-2 infectivity is a novel finding, 353 
corroborating the results of Jarikasem et al. (2013) who have reported a virucidal 354 
activity of a fraction containing β-sitosterol and stigmasterol against both HSV-1 and 355 
HSV-2. Furthermore, we have also evidenced the significant ability of carvacrol to 356 
inactivate extracellular HSV-2 particles either at 0 h or 2 h of incubation (Figure 3C). 357 
This data confirm the results of Jarikasem et al. (2013) who have previously shown the 358 
virucidal activity of carvacrol against HSV-1 particles. Since the anti-herpetic activity 359 
of carvacrol was previously reported in literature, we decided to gain further insights 360 
into β-sitosterol and cinnamaldehyde mode of antiviral action. To explore whether they 361 
target additional steps of the HSV-2 replicative cycle, specific cell assays we carried 362 
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out. As shown in Figure 4A, pretreatment of cells with both β-sitosterol and 363 
cinnamaldehyde did not produce any inhibitory effect indicating that upon treatment, 364 
the cells remained susceptible to viral infection (pre-treatment assay). This finding 365 
exclude that the compounds could act by stably interacting with a cellular component(s) 366 
thereby preventing its/their interaction with viral glycoproteins. To evaluate the 367 
possibility that the inhibitory activity is due, not only to a virucidal effect, but also to 368 
the ability of β-sitosterol to inhibit early steps of the virus replicative cycle, attachment 369 
and entry assays were performed. As reported in Figure 4B and 4C, a weak inhibitory 370 
activity, around 20-30%, was only observed when the cells were treated with a high 371 
dose of compounds (80 M) in both assays, whereas a dose response curve was 372 
obtained treating cells with heparin, a known inhibitor of attachment. 373 
These findings ruled out any effect β-sitosterol and cinnamaldehyde on virus attachment 374 
and entry. Then, we wished to investigate whether the compounds were able to block 375 
the cell-to-cell transmission of HSV-2 (post-treatment assay). When β-sitosterol and 376 
cinnamaldehyde were added to the cells after virus infection they strongly reduced the 377 
number of viral plaques as compared to the untreated cells with EC50 values of  6.9 M 378 
and 7.5 M, respectively (Figure 4D). This finding indicate their ability to prevent cell-379 
to-cell spread of HSV-2 in a dose-dependent manner at non toxic concentrations. 380 
Finally, both β-sitosterol and cinnamaldehyde also reduced the viral titer, in a dose-381 
response manner, when they were tested in a virus yield reduction assay, with EC50 382 
value of 3.64 M and 8.41 M, respectively (Figure 5). These data indicate their ability 383 
to inhibit multiple cycles of viral replication at high doses thus limiting the production 384 
of viral progenies. Acyclovir was used as standard positive drug of this assay. 385 
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Taken together, such antiviral properties might be useful in the setting of a productive 386 
infection in vivo, where T. capitatus extracts or its antiviral compounds might be able to 387 
prevent both cell-to-cell spread, which represents a major route of transmission for 388 
HSV-2 in vivo, and the transmission of extracellular free virus, which is often present in 389 
the site of infection at high titers (Dingwell et al., 1994). 390 
In conclusion, this study reports on the anti-herpetic activity of T. capitatus extracts and 391 
shows, for the first time, the ability of its isolated compounds β-sitosterol, 392 
cinnamaldehyde and carvacrol to inhibit infection by acyclovir-responsive and 393 
acyclovir-resistant HSV-2 strains. The mechanism of action of pure compounds mainly 394 
consists in direct inactivation of HSV-2 extracellular particles along with a reduced cell-395 
to-cell virus spread. Findings identified pure compounds from Thymus capitatus 396 
ethanolic extract as inhibitors of  HSV-2 infection suggesting their potential for 397 
treatment of herpetic lesions. 398 
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Figure captions 530 
Figure 1. HPLC chromatograms of β-sitosterol (A), cinnamaldehyde (B) and carvacrol 531 
(C) 532 
Figure 2. GC chromatogram of T. capitatus essential oil  533 
Figure 3. Evaluation of virus inactivation by β-sitosterol (panel A), cinnamaldehyde 534 
(panel B) and carvacrol (panel C) on infectious HSV-2 particles at 37 °C for 0 h or 2 h. 535 
On the y axis, the infectious titers are expressed as plaque-forming units per ml 536 
(PFU/ml). Error bars represent standard error of the mean (SEM) of 3 independent 537 
experiments. *p< 0.001 538 
Figure 4. Effect of β-sitosterol and cinnamaldehyde on viral replicative cycle. Pre-539 
treatment assay (A), attachment assay (B), entry assay (C) and post-treatment assay (D). 540 
Heparin was used as a known inhibitor of attachment. Acyclovir were used as standard 541 
positive drugs when it was added after infection. Error bars represent the SD of the 542 
mean of three independent experiments. 543 
Figure 5. Effect of β-sitosterol (panel A), cinnamaldehyde (panel B) or acyclovir (panel 544 
C) on multiple cycles of HSV-2 replication. Viral titers (expressed as PFU/ml) are 545 
shown as means plus standard error of the mean (SEM) for three independent 546 
experiments. *p< 0.05; ** p <0.01; ***p < 0.001 547 
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Table 1. Antiviral activity of Thymus capitatus extracts  
 
 Virus EC50a (µg/ml)  
– 95% C.I. b 
CC50c (µg/ml) SId 
Aqueous extract HSV-2 23.6 (15.5 - 30.2) > 300 > 12.6 
 HSV-1 
 
23.4 (14.3 - 32.4) > 300 > 12.7 
Ethanolic extract HSV-2 2.3 (1.4 - 3.8) 62.5 26.8 
 HSV-1 
 
16.6 (11.2 - 24.6) 58.5 3.5 
Essential oil HSV-2 18.6 (13.4 - 25.9) 129.1 6.9 
 HSV-1 
 
17.6 (6.5 - 27.5) 107.0 6.0 
a half maximal effective concentration 
b confidence interval 
c half maximal cytotoxic concentration 
d selectivity index 
 
 548 
 549 
 550 
Table 2. Antiviral activity of  purified compounds derived from Thymus capitatus 
ethanolic extract  
 
 Virus EC50a (µg/ml)  
– 95% C.I. b 
CC50c (µg/ml) SId 
-sitosterol HSV-2 2.7 (1.8 - 4.1) 212.8 76.2 
 HSV-2 ACV-re 
 
2.3 (2.1- 2.5) 212.8 90.9 
Cinnamaldehyde HSV-2 39.7 (30.4 - 51.8) 1126 28.3 
 HSV-2 ACV-r 
 
73.5 (47.3- 94.3) 1126 15.3 
Carvacrol HSV-2 51.9 (36.3-74.2) 632.9 12.1 
 HSV-2 ACV-r 
 
82.2 (62.3-108.5) 632.9 7.6 
Acyclovir HSV-2 0.7 (0.4-1.0) 754 1062 
 HSV-2 ACV-r 
 
336.9 (263.3-395.3) 754 2.2 
a half maximal effective concentration 
b confidence interval 
c half maximal cytotoxic concentration 
d selectivity index 
e HSV-2 acyclovir resistant strain 
 551 
